Comparison of cases of systemic AIDS-related lymphoma between 1993-1994 and 1997-1998 in three French hospitals
| Characteristic . | 1993-1994 . | 1997-1998 . | P . |
|---|---|---|---|
| No. of males (%) | 59 (93.7) | 37 (88.1) | .479 |
| Risk group | .335 | ||
| Homosexual/Bisexual | 40 (63.5) | 25 (59.5) | |
| IV drug use | 4 (6.3) | 3 (7.1) | |
| Heterosexual | 7 (11.1) | 6 (14.3) | |
| Other | 9 (14.3) | 2 (4.8) | |
| Age, y3-150 | 39 (23-74) | 38 (26-71) | .912 |
| Prior known HIV infection | 61 (96.8) | 39 (92.9) | |
| Time from HIV diagnosis, mo3-150 | 75 (0-133) | 98 (0-161) | .014 |
| No prior AIDS disease | 31 (50.0) | 25 (61.0) | .274 |
| Length of prior AIDS disease, mo3-150 | 1 (0-106) | 0 (0-144) | .425 |
| CD4 count/μL3-150 | 63 (2-777) | 191 (1-966) | .002 |
| HIV viral load (median) | — | 29 000 | |
| Prior antiretroviral therapy | 51 (83.6) | 29 (72.5) | .181 |
| Length of antiretroviral therapy, mo3-150 | 31 (0-95) | 44 (0-115) | .034 |
| DLBCL | 49 (79.0) | 26 (63.4) | .17 |
| BL | 11 (17.7) | 11 (26.8) | |
| Polymorphic lymphoid proliferation | 2 (3.2) | 4 (9.8) | |
| Extranodal localization | 53 (84.1) | 29 (69.0) | .067 |
| Bone marrow involvement3-151 | 8 (20.0) | 6 (20.7) | .067 |
| LDH at least 2N | 25 (41.7) | 15 (41.7) | 1.000 |
| Total | 63 | 42 |
| Characteristic . | 1993-1994 . | 1997-1998 . | P . |
|---|---|---|---|
| No. of males (%) | 59 (93.7) | 37 (88.1) | .479 |
| Risk group | .335 | ||
| Homosexual/Bisexual | 40 (63.5) | 25 (59.5) | |
| IV drug use | 4 (6.3) | 3 (7.1) | |
| Heterosexual | 7 (11.1) | 6 (14.3) | |
| Other | 9 (14.3) | 2 (4.8) | |
| Age, y3-150 | 39 (23-74) | 38 (26-71) | .912 |
| Prior known HIV infection | 61 (96.8) | 39 (92.9) | |
| Time from HIV diagnosis, mo3-150 | 75 (0-133) | 98 (0-161) | .014 |
| No prior AIDS disease | 31 (50.0) | 25 (61.0) | .274 |
| Length of prior AIDS disease, mo3-150 | 1 (0-106) | 0 (0-144) | .425 |
| CD4 count/μL3-150 | 63 (2-777) | 191 (1-966) | .002 |
| HIV viral load (median) | — | 29 000 | |
| Prior antiretroviral therapy | 51 (83.6) | 29 (72.5) | .181 |
| Length of antiretroviral therapy, mo3-150 | 31 (0-95) | 44 (0-115) | .034 |
| DLBCL | 49 (79.0) | 26 (63.4) | .17 |
| BL | 11 (17.7) | 11 (26.8) | |
| Polymorphic lymphoid proliferation | 2 (3.2) | 4 (9.8) | |
| Extranodal localization | 53 (84.1) | 29 (69.0) | .067 |
| Bone marrow involvement3-151 | 8 (20.0) | 6 (20.7) | .067 |
| LDH at least 2N | 25 (41.7) | 15 (41.7) | 1.000 |
| Total | 63 | 42 |